<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272217</url>
  </required_header>
  <id_info>
    <org_study_id>HCRN GU15-215</org_study_id>
    <nct_id>NCT03272217</nct_id>
    <nct_alias>NCT03133390</nct_alias>
  </id_info>
  <brief_title>Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer</brief_title>
  <official_title>A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arjun Balar, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche-Genentech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in&#xD;
      metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center trial.&#xD;
&#xD;
      INVESTIGATIONAL TREATMENT:&#xD;
&#xD;
      Eligible patients will be receive atezolizumab 1200 mg IV flat dose plus bevacizumab 15 mg/kg&#xD;
      IV every 21 days&#xD;
&#xD;
      21 days equals 1 cycle of therapy and patients will be eligible to continue treatment until&#xD;
      progressive disease by RECIST v1.1 or unacceptable toxicity for up to 24 months.&#xD;
&#xD;
      To demonstrate adequate organ function, all screening labs must be obtained within 14 days&#xD;
      prior to Cycle 1 Day 1 (C1D1) of treatment:&#xD;
&#xD;
      Hematological:&#xD;
&#xD;
        -  Absolute Neutrophil Count (ANC): ≥ 1,000 K/mm^3&#xD;
&#xD;
        -  Hemoglobin (Hgb): ≥ 9.0 g/dL&#xD;
&#xD;
        -  Absolute Lymphocyte Count: ≥ 500/uL&#xD;
&#xD;
        -  Platelet Count: ≥ 100,000/uL&#xD;
&#xD;
      Renal:&#xD;
&#xD;
        -  Calculated Creatinine Clearance: serum creatinine &lt; 2.5 or ≥ 25 cc/min using a direct&#xD;
           method or the Cockcroft-Gault formula&#xD;
&#xD;
        -  Urinary Protein Excretion: &lt; 1.0 g/24 hours (as estimated by urine protein-creatinine&#xD;
           ratio)&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  Bilirubin: ≤ 1.5 × upper limit of normal (ULN) (patients with known Gilbert's Disease&#xD;
           who have serum bilirubin ≤ 3.0 x ULN may be enrolled)&#xD;
&#xD;
        -  Aspartate aminotransferase (AST): ≤ 2.5 × ULN (5.0 x ULN if liver involvement)&#xD;
&#xD;
        -  Alanine aminotransferase (ALT): ≤ 2.5 × ULN (5.0 x ULN if liver involvement)&#xD;
&#xD;
        -  Serum Albumin: ≥ 2.5 g/dL&#xD;
&#xD;
      Coagulation:&#xD;
&#xD;
        -  International Normalized Ratio (INR) or Prothrombin Time (PT); Activated Partial&#xD;
           Thromboplastin Time (aPTT): ≤ 1.5 × ULN (NOTE: This applies only to patients who are not&#xD;
           receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation&#xD;
           should be on a stable dose)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 13, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>date at time of randomization up to 1 year</time_frame>
    <description>Comparison of 1-year overall survival (OS) rates for cisplatin-ineligible patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The objective response rate is the proportion of all patients with confirmed PR or CR according to RECIST 1.1, from the start of treatment until disease progression/recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>1 year</time_frame>
    <description>The period measured from the time that measurement criteria are met for complete response until the first date that recurrent disease is objectively documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>up to 25 months</time_frame>
    <description>The disease control rate is the proportion of all patients with stable disease (SD) for 8 weeks, or partial response (PR), or complete response (CR) according to RECIST 1.1, from the start of treatment until disease progression/recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>A measurement from the date of randomization until the criteria for disease progression is met as defined by RECIST 1.1 or death occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Safety and Toxicity by CTCAEv4</measure>
    <time_frame>2 years</time_frame>
    <description>by CTCAEv4</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A - Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 1200 mg (flat dose) IV every 21 days</description>
    <arm_group_label>Arm A - Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>MPDL3280A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15 mg/kg IV every 21 days</description>
    <arm_group_label>Arm A - Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        Patient must meet all of the following applicable inclusion criteria to participate in this&#xD;
        study:&#xD;
&#xD;
          -  Written informed consent and Health Insurance Portability and Accountability Act of&#xD;
             1996 (HIPAA) authorization for release of personal health information.&#xD;
&#xD;
          -  As determined by the enrolling physician or protocol designee, ability of the patient&#xD;
             to understand and comply with study procedures for the entire length of the study&#xD;
&#xD;
          -  Age ≥ 18 years at the time of consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2 within 28&#xD;
             days prior to registration&#xD;
&#xD;
          -  Histological or cytological evidence urothelial (transitional cell) carcinoma of the&#xD;
             renal pelvis, ureter, bladder or urethra&#xD;
&#xD;
          -  Locally advanced/unresectable disease as determined by site attending urologic&#xD;
             oncologist or metastatic disease&#xD;
&#xD;
          -  Evaluable untreated tumor tissue for biomarker analysis. Untreated tumor tissue is&#xD;
             defined as no intervening intravesical or systemic therapy since acquisition. Patients&#xD;
             without tissue available must be willing and safe to undergo biopsy repeat biopsy&#xD;
             (core needle or excisional) prior to enrollment. Subjects with &lt; 25 slides may be&#xD;
             enrolled after discussion with the sponsor-investigator or co-investigator.&#xD;
&#xD;
          -  Willing to undergo a core needle or excisional biopsy on-treatment. Patients will be&#xD;
             assessed at the time of biopsy for safety of undergoing the procedure&#xD;
&#xD;
          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             v1.1 within 28 days prior to registration&#xD;
&#xD;
          -  No prior chemotherapy for locally advanced or metastatic urothelial cancer&#xD;
&#xD;
               -  Perioperative chemotherapy previously administered in the neoadjuvant and/or&#xD;
                  adjuvant setting is permitted&#xD;
&#xD;
               -  Prior chemotherapy administered in the context of chemoradiation as definitive&#xD;
                  treatment for bladder preservation is also permitted, provided that disease&#xD;
                  progression outside the prior radiotherapy field is demonstrated histologically&#xD;
                  or cytologically&#xD;
&#xD;
          -  Ineligible for cisplatin as defined by presence of one or more of the following:&#xD;
&#xD;
               -  (Impaired renal function [≤ 60 cc/min]. Glomerular filtration rate (GFR) should&#xD;
                  be assessed by direct measurement [i.e., creatinine clearance or&#xD;
                  ethylenediaminetetra-acetate] or, if not available, by calculation from&#xD;
                  serum/plasma creatinine by Cockroft-Gault equation)&#xD;
&#xD;
               -  Grade ≥ 2 hearing Loss (measured by loss of &gt;25 dB at two contiguous frequencies&#xD;
                  in at least one ear for patients undergoing serial audiometry testing)&#xD;
&#xD;
               -  Grade ≥ 2 peripheral neuropathy&#xD;
&#xD;
               -  ECOG Performance Status of 2&#xD;
&#xD;
               -  Solitary Kidney&#xD;
&#xD;
               -  Refusing Cisplatin-based chemotherapy&#xD;
&#xD;
          -  If palliative radiotherapy administered, completion of palliative radiation therapy ≥&#xD;
             2 weeks prior to Cycle 1 Day 1 of protocol therapy&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test within 28&#xD;
             days prior to registration.&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to abstain from&#xD;
             heterosexual intercourse or to use 2 forms of effective methods of contraception from&#xD;
             the time of informed consent until 150 days (5 months) after discontinuation of&#xD;
             atezolizumab or 180 days (6 months) after discontinuation of bevacizumab. The two&#xD;
             contraception methods can be comprised of two barrier methods, or a barrier method&#xD;
             plus a hormonal method&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        Patients meeting any of the criteria below may not participate in the study:&#xD;
&#xD;
          -  Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3&#xD;
             weeks prior to initiation of study treatment; the following exceptions are allowed:&#xD;
&#xD;
               -  Palliative radiotherapy for bone metastases or soft tissue lesions should be&#xD;
                  completed &gt; 7 days prior to baseline imaging&#xD;
&#xD;
               -  Hormone-replacement therapy or oral contraceptives&#xD;
&#xD;
          -  Treatment with any other investigational agent or participation in another clinical&#xD;
             trial with therapeutic intent within 28 days prior to enrollment&#xD;
&#xD;
          -  Active or untreated central nervous system (CNS) metastases or leptomeningeal disease&#xD;
             as determined by computed tomography (CT) scan or magnetic resonance imaging (MRI)&#xD;
             evaluation during screening and prior radiographic assessments. Patients with treated&#xD;
             asymptomatic CNS metastases are eligible, provided they meet all of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Evaluable or measurable disease outside the CNS&#xD;
&#xD;
               -  No metastases to midbrain, pons, medulla, cerebellum, or within 10 mm of the&#xD;
                  optic apparatus (optic nerves and chiasm)&#xD;
&#xD;
               -  No history of intracranial or spinal cord hemorrhage&#xD;
&#xD;
               -  No evidence of significant vasogenic edema&#xD;
&#xD;
               -  No ongoing requirement for dexamethasone as therapy for CNS disease;&#xD;
                  anticonvulsants at a stable dose allowed&#xD;
&#xD;
               -  No stereotactic radiation, whole-brain radiation within 4 weeks prior to Cycle 1&#xD;
                  Day 1&#xD;
&#xD;
               -  Patients with central nervous system (CNS) metastases treated by neurosurgical&#xD;
                  resection or brain biopsy within 3 months prior to Cycle 1 Day 1 will be excluded&#xD;
&#xD;
               -  Radiographic demonstration of interim stability (i.e., no progression) between&#xD;
                  the completion of CNS-directed therapy and the screening radiographic study&#xD;
&#xD;
               -  Screening CNS radiographic study ≥ 4 weeks since completion of radiotherapy or&#xD;
                  surgical resection and ≥ 2 weeks since discontinuation of corticosteroids&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
               -  Patients requiring pain medication must be on a stable regimen at study entry&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently)&#xD;
&#xD;
               -  Patients with indwelling drainage catheters are allowed.&#xD;
&#xD;
          -  Uncontrolled hypercalcemia (&gt; 1.5 mmol/L ionized calcium or Ca &gt; 12 mg/dL or corrected&#xD;
             serum calcium &gt; ULN) or symptomatic hypercalcemia requiring continued use of&#xD;
             bisphosphonate therapy or denosumab. NOTE: Patients with asymptomatic hypercalcemia&#xD;
             controlled with medical therapy are eligible.&#xD;
&#xD;
               -  Patients who are receiving bisphosphonate therapy or denosumab specifically to&#xD;
                  prevent skeletal events and who do not have a history of clinically significant&#xD;
                  hypercalcemia are eligible.&#xD;
&#xD;
               -  Patients who are receiving denosumab prior to enrollment must be willing and&#xD;
                  eligible to receive a bisphosphonate instead while in the study.&#xD;
&#xD;
          -  Malignancies other than urothelial cancer within 5 years prior to Cycle 1 Day 1, with&#xD;
             the exception of those with a negligible risk of metastasis or death treated with&#xD;
             expected curative outcome (such as adequately treated carcinoma in situ of the cervix,&#xD;
             basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically&#xD;
             with curative intent) or localized prostate cancer treated with curative intent and&#xD;
             absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer&#xD;
             (T1/T2a, Gleason score ≤ 3 + 4, and PSA ≤ 0.5 ng/mL undergoing active surveillance and&#xD;
             treatment naive)&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
          -  Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or any component of the atezolizumab or bevacizumab formulation&#xD;
&#xD;
          -  History of autoimmune disease, including but not limited to myasthenia gravis,&#xD;
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid&#xD;
             syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré&#xD;
             syndrome, multiple sclerosis, vasculitis, or glomerulonephritis&#xD;
&#xD;
               -  Subjects with a history of autoimmune-related hypothyroidism on a stable dose of&#xD;
                  thyroid replacement hormone may be eligible for this study.&#xD;
&#xD;
               -  Subjects with controlled Type I diabetes mellitus on a stable dose of insulin&#xD;
                  regimen may be eligible for this study.&#xD;
&#xD;
               -  Subjects with a history of celiac disease may be eligible if controlled with&#xD;
                  diet.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active&#xD;
             pneumonitis on screening chest CT scan&#xD;
&#xD;
               -  History of radiation pneumonitis in the radiation field (fibrosis) is permitted.&#xD;
&#xD;
          -  History of confirmed positive test for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patients with active hepatitis B virus (HBV) (chronic or acute, defined as having a&#xD;
             positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C virus&#xD;
             (HCV)&#xD;
&#xD;
               -  Patients with past HBV infection or resolved HBV infection (defined as the&#xD;
                  presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible&#xD;
&#xD;
               -  Patients positive for HCV antibody are eligible only if polymerase chain reaction&#xD;
                  is negative for HCV RNA&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Severe infections within 4 weeks prior to Cycle 1 Day 1, including but not limited to&#xD;
             hospitalization for complications of infection, bacteremia, or severe pneumonia&#xD;
&#xD;
          -  Signs or symptoms of active infection within 2 weeks prior to C1D1&#xD;
&#xD;
          -  Received therapeutic oral or IV antibiotics within 1 week prior to C1D1&#xD;
&#xD;
               -  Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary&#xD;
                  tract infection or to prevent chronic obstructive pulmonary disease exacerbation)&#xD;
                  are eligible&#xD;
&#xD;
          -  New York Heart Association Congestive Heart Failure Class II or greater&#xD;
&#xD;
          -  Myocardial infarction, unstable angina or unstable arrhythmias within 3 months of&#xD;
             enrollment.&#xD;
&#xD;
          -  History of stroke or TIA within 3 months of enrollment&#xD;
&#xD;
          -  Other clinically significant arterial vascular disease within 6 months of enrollment&#xD;
             (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial&#xD;
             thrombosis). Prior history of adequately treated venous thromboembolism &gt; 7 days prior&#xD;
             to C1D1 on stable dose of therapeutic anticoagulation is permitted&#xD;
&#xD;
          -  Patients with known coronary artery disease, congestive heart failure not meeting the&#xD;
             above criteria, or left ventricular ejection fraction &lt; 50% must be on a stable&#xD;
             medical regimen that is optimized in the opinion of the treating physician, in&#xD;
             consultation with a cardiologist if appropriate.&#xD;
&#xD;
          -  Major surgical procedure other than for diagnosis within 28 days prior to C1D1 or&#xD;
             anticipation of need for a major surgical procedure during the course of the study&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplant&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before C1D1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the subject at high risk from treatment&#xD;
             complications&#xD;
&#xD;
        ATEZOLIZUMAB-SPECIFIC EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including&#xD;
             anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies&#xD;
&#xD;
               -  Prior cancer vaccines and cellular immunotherapy are permitted.&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including but not limited to IFNs,&#xD;
             interleukin [IL]-2) within 6 weeks or five half-lives of the drug, whichever is&#xD;
             shorter, prior to C1D1&#xD;
&#xD;
          -  Treatment with systemic corticosteroids or other systemic immunosuppressive&#xD;
             medications (including but not limited to prednisone, dexamethasone, cyclophosphamide,&#xD;
             azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF]&#xD;
             agents) within 2 weeks prior to C1D1, or anticipated requirement for systemic&#xD;
             immunosuppressive medications during the trial&#xD;
&#xD;
               -  Patients who have received acute, low-dose, systemic immunosuppressant&#xD;
                  medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled&#xD;
&#xD;
               -  The use of inhaled corticosteroids, physiologic replacement doses of&#xD;
                  glucocorticoids (i.e., for adrenal insufficiency), and mineralocorticoids (e.g.,&#xD;
                  fludrocortisone for adrenal insufficiency) is allowed&#xD;
&#xD;
        BEVACIZUMAB-SPECIFIC EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Inadequately controlled hypertension (defined as persistent systolic blood pressure&#xD;
             (SBP) &gt; 150 and/or diastolic blood pressure (DBP) &gt; 100 mmHg)&#xD;
&#xD;
          -  Prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          -  Current or recent (within 10 days of study enrollment) use of aspirin (&gt; 325 mg/day),&#xD;
             clopidogrel (&gt; 75 mg/day), or current or recent (within 10 days prior to first dose of&#xD;
             bevacizumab) use of therapeutic oral or parenteral anticoagulants or thrombolytic&#xD;
             agents for therapeutic purposes&#xD;
&#xD;
          -  History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month&#xD;
             of study enrollment&#xD;
&#xD;
          -  Minor surgical procedure within 7 calendar days prior to C1D1&#xD;
&#xD;
          -  History of abdominal or tracheoesophageal fistula or gastrointestinal perforation&#xD;
             within 6 months prior to enrollment&#xD;
&#xD;
          -  Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine&#xD;
             parenteral hydration, parenteral nutrition, or tube feeding&#xD;
&#xD;
          -  Evidence of abdominal free air not explained by paracentesis or recent surgical&#xD;
             procedure&#xD;
&#xD;
          -  Serious non-healing or dehiscing wound, active ulcer, or untreated or non-healing bone&#xD;
             fracture&#xD;
&#xD;
          -  On-going gross hematuria associated with clots&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjun Balar, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona at Dignity Health St. Joseph</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Cancer Center University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosiercancer.org</url>
    <description>Hoosier Cancer Research Network Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 1, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Arjun Balar, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Atezolizumab</keyword>
  <keyword>MPDL3280A</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Cisplatin-Ineligible</keyword>
  <keyword>Anti-PD-L1 Antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

